Financial reports
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
4 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
8 Aug 18
Current reports
8-K
Termination of a Material Definitive Agreement
17 Nov 20
8-K
MyoKardia Reports Third Quarter 2020 Financial Results
5 Nov 20
8-K
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
5 Oct 20
8-K
MyoKardia Reports Second Quarter 2020 Financial Results
4 Aug 20
8-K
Submission of Matters to a Vote of Security Holders
24 Jun 20
8-K
MyoKardia Announces Proposed Public Offering of Common Stock
14 May 20
8-K
Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo
11 May 20
8-K
MyoKardia Reports First Quarter 2020 Financial Results
6 May 20
8-K
MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten
30 Mar 20
8-K
MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic
26 Mar 20
Registration and prospectus
15-12B
Securities registration termination
27 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
POSASR
Automatic shelf registration (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
SC 14D9/A
Tender offer solicitation (amended)
17 Nov 20
25-NSE
Exchange delisting
17 Nov 20
SC TO-T/A
Third party tender offer statement (amended)
17 Nov 20
Proxies
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
DEFA14A
Additional proxy soliciting materials
24 Apr 19
DEFA14A
Additional proxy soliciting materials
24 Apr 19
DEF 14A
Definitive proxy
24 Apr 19
DEF 14A
Definitive proxy
17 Apr 18
DEFA14A
Additional proxy soliciting materials
17 Apr 18
DEF 14A
Definitive proxy
25 Apr 17
DEFA14A
Additional proxy soliciting materials
25 Apr 17
Other
SEC STAFF
SEC staff action: Order
26 Feb 20
SEC STAFF
SEC staff action: Order
10 Feb 20
EFFECT
Notice of effectiveness
21 Jul 17
CORRESP
Correspondence with SEC
19 Jul 17
UPLOAD
Letter from SEC
13 Jul 17
EFFECT
Notice of effectiveness
19 Jan 17
CORRESP
Correspondence with SEC
18 Jan 17
UPLOAD
Letter from SEC
17 Jan 17
EFFECT
Notice of effectiveness
27 Sep 16
CORRESP
Correspondence with SEC
26 Sep 16
Ownership
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
27 Nov 20
4
David P Meeker
19 Nov 20
4
Robert Scott McDowell
19 Nov 20
4
Taylor C. Harris
19 Nov 20
4
SUNIL AGARWAL
19 Nov 20
4
William Fairey
19 Nov 20
4
Jake Bauer
19 Nov 20
4
MARK L PERRY
19 Nov 20
4
Kimberly J Popovits
19 Nov 20
4
MARY B CRANSTON
19 Nov 20